Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Viking Therapeutics (VKTX) Non-cash Items: 2015-2025

Historic Non-cash Items for Viking Therapeutics (VKTX) over the last 9 years, with Sep 2025 value amounting to $75.0 million.

  • Viking Therapeutics' Non-cash Items rose 3681.45% to $75.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $75.0 million, marking a year-over-year increase of 3681.45%. This contributed to the annual value of $141.3 million for FY2024, which is 5616.50% up from last year.
  • Per Viking Therapeutics' latest filing, its Non-cash Items stood at $75.0 million for Q3 2025, which was down 2.10% from $76.6 million recorded in Q2 2025.
  • Viking Therapeutics' 5-year Non-cash Items high stood at $49.6 billion for Q2 2023, and its period low was $1.4 million during Q1 2022.
  • Over the past 3 years, Viking Therapeutics' median Non-cash Items value was $75.0 million (recorded in 2025), while the average stood at $6.7 billion.
  • Its Non-cash Items has fluctuated over the past 5 years, first surged by 1,726,714.85% in 2023, then plummeted by 99.99% in 2024.
  • Quarterly analysis of 5 years shows Viking Therapeutics' Non-cash Items stood at $2.9 billion in 2021, then slumped by 99.29% to $20.5 million in 2022, then surged by 203.24% to $62.2 million in 2023, then skyrocketed by 127.13% to $141.3 million in 2024, then surged by 3,681.45% to $75.0 million in 2025.
  • Its last three reported values are $75.0 million in Q3 2025, $76.6 million for Q2 2025, and $66.4 million during Q1 2025.